Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Declines By 76.5%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 7,300 shares, adecreaseof76.5% from the July 15th total of 31,000 shares. Currently,0.1% of the shares of the stock are short sold. Based on an average daily volume of 88,400 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 88,400 shares, the short-interest ratio is presently 0.1 days. Currently,0.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen began coverage on shares of Bio-Path in a research note on Wednesday, May 21st. They issued a “sell” rating for the company.

Bio-Path Stock Down 5.3%

BPTH opened at $0.13 on Friday. The company has a fifty day moving average of $0.16 and a 200 day moving average of $0.22. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $3.39.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.